Dow Jones
35.950,89 +520,47 (+1,47%) Nasdaq
14.226,22 -32,27 (-0,23%) Nikkei 225
33.456,62 -30,27 (-0,09%) EUR/USD
1,0904 +0,0011 (+0,10%) Bitcoin EUR
34.547,41 -126,41 (-0,36%) CMC Crypto 200
780,30 -3,34 (-0,43%)
Bristol-Myers Squibb Company (BMY)
Dopo ore:
| Chiusura precedente | 48,72 |
| Aperto | 48,78 |
| Denaro | 49,31 x 900 |
| Lettera | 49,78 x 1800 |
| Min-Max giorno | 48,25 - 49,40 |
| Intervallo di 52 settimane | 48,25 - 81,44 |
| Volume | |
| Media Volume | 12.835.788 |
| Capitalizzazione | 100,476B |
| Beta (5 anni mensile) | 0,37 |
| Rapporto PE (ttm) | 12,53 |
| EPS (ttm) | 3,94 |
| Prossima data utili | 02 feb 2024 |
| Rendimento e dividendo (futuro) | 2,28 (4,68%) |
| Data ex dividendo | 05 ott 2023 |
| Stima target 1A | 57,45 |
GlobeNewswireArbutus Appoints Two New Executives
Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced the appointment of Dr. Karen Sims as Chief Medical Officer and Mr. Chri
GlobeNewswireiVexSol® Closes $23.8M Series A-3 Financing; Funds to Revolutionize the Production of Lentiviral Vectors
LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- iVexSol Inc., a technology-based lentiviral vector (LVV) contract development and manufacturing organization (CDMO), announced $23.8 million in Series A-3 funding. New investors Bristol Myers Squibb (NYSE: BMY), Charles River Laboratories (NYSE: CRL) and Asahi Kasei Medical, a division of Asahi Kasei (NYSE: AHKSY), join existing investors which include Casdin Capital and BioLife Solutions (Nasdaq: BLFS) to close Series A financing at a total of
